Literature DB >> 3282185

Complications in cerebral angiography with iohexol (Omnipaque) and meglumine metrizoate (Isopaque cerebral).

I O Skalpe1.   

Abstract

The complications of cerebral angiography have been recorded in 1509 examinations with metrizoate (Isopaque Cerebral) and in 1000 examinations with iohexol (Omnipaque). The frequency of complications was 2.0 percent for metrizoate and 1.3 percent for iohexol. Permanent sequelae were seen in 4 patients, 3 in the metrizoate and one in the iohexol group. One of these patients died, probably from thromboembolism. Blood coagulation parameters were studied during the angiography in 22 patients and only minor, probably clinically insignificant changes were found, with no difference between the two contrast media.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282185     DOI: 10.1007/bf00341947

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  19 in total

1.  Embolic complications in cerebral angiography with the catheter technique.

Authors:  S Cronqvist; H O Efsing; E Palacios
Journal:  Acta Radiol Diagn (Stockh)       Date:  1970-03

2.  Intravascular contrast injection in ischaemic lesions. II. Effect on prognosis.

Authors:  B E Kendall; P Pullicino
Journal:  Neuroradiology       Date:  1980       Impact factor: 2.804

3.  Complications of cerebral angiography.

Authors:  H Olivecrona
Journal:  Neuroradiology       Date:  1977-12-31       Impact factor: 2.804

4.  Cerebral arterial constriction due to contrast media.

Authors:  G H du Boulay; A Wallis
Journal:  Acta Radiol Suppl       Date:  1986

5.  Neurotoxicity of iohexol: a new nonionic contrast medium.

Authors:  R N Bryan; R S Centeno; N Hershkowitz; R J Poelstra; M S Osato
Journal:  Radiology       Date:  1982-11       Impact factor: 11.105

6.  Angiography with metrizamide in neuroradiological examinations.

Authors:  J Valk
Journal:  Diagn Imaging       Date:  1979

7.  Iohexol compared to meglumine-Ca-metrizoate in common carotid angiography. A randomized double blind cross-over study in man.

Authors:  P Nakstad; O Sortland; O Aaserud
Journal:  Neuroradiology       Date:  1983       Impact factor: 2.804

8.  Intravenous digital subtraction angiography with iohexol (Omnipaque) and sodium meglumin diatrizoate (Urografin).

Authors:  A Karle; J Fries; S Laulund; E Andrew
Journal:  Diagn Imaging Clin Med       Date:  1986

9.  Summary of U.S. and European intravascular experience with iohexol based on the clinical trial program.

Authors:  K Dahlstrom; D D Shaw; W Clauss; E Andrew; K Sveen
Journal:  Invest Radiol       Date:  1985 Jan-Feb       Impact factor: 6.016

10.  Complications in cerebral angiography. A comparison between the non-ionic contrast medium iohexol and meglumine metrizoate (Isopaque Cerebral).

Authors:  I O Skalpe; I M Anke
Journal:  Neuroradiology       Date:  1983       Impact factor: 2.804

View more
  4 in total

1.  Quality improvement guidelines for adult diagnostic neuroangiography. Cooperative study between the ASNR, ASITN, and the SCVIR. American Society of Neuroradiology. American Society of Interventional and Therapeutic Neuroradiology. Society of Cardiovascular and Interventional Radiology.

Authors: 
Journal:  AJNR Am J Neuroradiol       Date:  2000-01       Impact factor: 3.825

2.  Digital subtraction angiography (DSA). Work load and financial implications for a neuroradiology department.

Authors:  D P Kingsley; P Butler; G M Rowe; R C Travis; I G Wylie
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

Review 3.  [Recent studies concerning treatment of acute, ischemic infarcts].

Authors:  I Q Grunwald; T Struffert; U Dorenbeck; P Papanagiotou; W Reith
Journal:  Radiologe       Date:  2005-05       Impact factor: 0.635

4.  WebParc: a tool for analysis of the topography and volume of stroke from MRI.

Authors:  David N Kennedy; Christian Haselgrove; Nikos Makris; Donald M Goldin; Michael H Lev; David Caplan; Verne S Caviness
Journal:  Med Biol Eng Comput       Date:  2010-03       Impact factor: 2.602

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.